{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:47:01Z","timestamp":1767649621852},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,14]]},"DOI":"10.7759\/cureus.40396","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T08:04:26Z","timestamp":1686729866000},"source":"Crossref","is-referenced-by-count":2,"title":["A Rare Case of Opsoclonus Myoclonus Ataxia Syndrome Post Viral Illness"],"prefix":"10.7759","author":[{"given":"Nauka S","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purva C","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ummayhany F","family":"Bharmal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maliha I","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199206000-00002","article-title":"The neurobiology of the opsoclonus-myoclonus syndrome","volume":"15","author":"Pranzatelli MR","year":"1992","unstructured":"Pranzatelli MR. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol. 1992, 15:186-228. 10.1097\/00002826-199206000-00002","journal-title":"Clin Neuropharmacol"},{"key":"ref2","unstructured":"National Organization for Rare Disorders. opsoclonus-myoclonus syndrome. (2019). Accessed: February 28, 2023: https:\/\/rarediseases.org\/rare-diseases\/opsoclonus-myoclonus-syndrome\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100106","article-title":"The movement disorder of adult opsoclonus","volume":"10","author":"Caviness JN","year":"1995","unstructured":"Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord. 1995, 10:22-7. 10.1002\/mds.870100106","journal-title":"Mov Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.1173","article-title":"Adult-onset opsoclonus-myoclonus syndrome","volume":"69","author":"Klaas JP","year":"2012","unstructured":"Klaas JP, Ahlskog JE, Pittock SJ, et al.. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012, 69:1598-607. 10.1001\/archneurol.2012.1173","journal-title":"Arch Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4607","article-title":"Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies","volume":"73","author":"Armangu\u00e9 T","year":"2016","unstructured":"Armangu\u00e9 T, Sabater L, Torres-Vega E, et al.. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016, 73:417-24. 10.1001\/jamaneurol.2015.4607","journal-title":"JAMA Neurol"},{"key":"ref6","article-title":"Harrison's principles of internal medicine","author":"Kasper D","year":"2015","unstructured":"Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison's principles of internal medicine. McGraw Hill, New York, NY; 2015."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9138-7","article-title":"Update on opsoclonus-myoclonus syndrome in adults","volume":"266","author":"Oh SY","year":"2019","unstructured":"Oh SY, Kim JS, Dieterich M. Update on opsoclonus-myoclonus syndrome in adults. J Neurol. 2019, 266:1541-8. 10.1007\/s00415-018-9138-7","journal-title":"J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(97)70272-5","article-title":"Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues","volume":"130","author":"Connolly AM","year":"1997","unstructured":"Connolly AM, Pestronk A, Mehta S, Pranzatelli MR 3rd, Noetzel MJ. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr. 1997, 130:878-84. 10.1016\/s0022-3476(97)70272-5","journal-title":"J Pediatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(17)30130-X","article-title":"Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial","volume":"2","author":"de Alarcon PA","year":"2018","unstructured":"de Alarcon PA, Matthay KK, London WB, et al.. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018, 2:25-34. 10.1016\/S2352-4642(17)30130-X","journal-title":"Lancet Child Adolesc Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-011-0098-6","article-title":"Rituximab","volume":"48","author":"Borker A","year":"2011","unstructured":"Borker A, Choudhary N. Rituximab. Indian Pediatr. 2011, 48:627-32. 10.1007\/s13312-011-0098-6","journal-title":"Indian Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0883073808324217","article-title":"Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil","volume":"24","author":"Pranzatelli MR","year":"2009","unstructured":"Pranzatelli MR, Tate ED, Travelstead AL, et al.. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol. 2009, 24:316-22. 10.1177\/0883073808324217","journal-title":"J Child Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2006.02.008","article-title":"Neuroblastoma found in a 4-year-old after rituximab therapy for opsoclonus-myoclonus","volume":"35","author":"Chang BH","year":"2006","unstructured":"Chang BH, Koch T, Hopkins K, Malempati S. Neuroblastoma found in a 4-year-old after rituximab therapy for opsoclonus-myoclonus. Pediatr Neurol. 2006, 35:213-5. 10.1016\/j.pediatrneurol.2006.02.008","journal-title":"Pediatr Neurol"},{"key":"ref13","unstructured":"Genetic and Rare Diseases Information Center. opsoclonus-myoclonus syndrome. (2019). Accessed: October 14, 2019: https:\/\/rarediseases.info.nih.gov\/diseases\/10009\/opsoclonus-myoclonus-syndrome."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus A","year":"2011","unstructured":"Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics. 2011, 128:e388-94. 10.1542\/peds.2010-3114","journal-title":"Pediatrics"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1542\/peds.109.1.86","article-title":"Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae","volume":"109","author":"Mitchell WG","year":"2002","unstructured":"Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al.. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics. 2002, 109:86-98.","journal-title":"Pediatrics"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4757","article-title":"New findings in adult opsoclonus-myoclonus syndrome","volume":"73","author":"Honnorat J","year":"2016","unstructured":"Honnorat J. New findings in adult opsoclonus-myoclonus syndrome. JAMA Neurol. 2016, 73:381-2. 10.1001\/jamaneurol.2015.4757","journal-title":"JAMA Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2008.03.005","article-title":"Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase","volume":"110","author":"Markakis I","year":"2008","unstructured":"Markakis I, Alexiou E, Xifaras M, Gekas G, Rombos A. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin Neurol Neurosurg. 2008, 110:619-21. 10.1016\/j.clineuro.2008.03.005","journal-title":"Clin Neurol Neurosurg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.2.279","article-title":"Parainfectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective","volume":"74","author":"Glatz K","year":"2003","unstructured":"Glatz K, Meinck HM, Wildemann B. Parainfectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective. J Neurol Neurosurg Psychiatry. 2003, 74:279-80. 10.1136\/jnnp.74.2.279","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/136805-a-rare-case-of-opsoclonus-myoclonus-ataxia-syndrome-post-viral-illness","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:30Z","timestamp":1707508950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/136805-a-rare-case-of-opsoclonus-myoclonus-ataxia-syndrome-post-viral-illness"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.40396","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,14]]}}}